Results: Lung tumours and circulating blood were harvested from mice, followed by analysis of global epigenetic modifications, and for metabolic enzymes. The metabolic profile of lung tumours harvested from CRISPR/Cas9 mice that lack expression of Lkb1, p53 and express enhanced Kras, was significantly different from the metabolic profile of lungs harvested from control mice, favouring a switch from glycolysis to mitochondrial metabolism. Acetylation and methylation modifications to histones 3 (H3) and H4 were significantly different compared to control mice, as was the macrophage activation profiles. Conclusion: The goal of our study was to 1) identify and characterize aberrant metabolic and epigenetic processes that allow for cancer adaptation and 2) develop non-invasive liquid biopsy that would provide rapid and affordable early diagnostic tool in clinic. We conclude from our study that patients with lung cancers that lack expression of LKB1 are likely to respond favourably to interventions that simultaneously target aberrant metabolism with modifiers of tumour epigenetic landscape. Our findings suggest that loss of LKB1 expression serves as a marker for lung cancers that are metabolically and epigenetically challenged.
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Results: A total of 2309 patients received ROS1 fusion detection and 51 (2.2%) patients had ROS1 rearrangement. There was no significant difference between ROS1 fusion-positive and fusion-negative cohorts in demographic data. For all patients, crizotinb-treated group had a higher overall response rate (ORR, 80.0%), disease control rate (DCR, 90.0%) and longer progression-free survival (PFS, 294 days) compared with the rates in pemetrexed-treated group (ORR, 40.8%; DCR, 71.4%; PFS, 179 days) and nonpemetrexed-treated group (ORR, 25.0%; DCR, 47.7%; PFS, 110 days). ORR, DCR and PFS were similar in three major ROS1 fusion patterns. For first-line treatment, patients received pemetrexed had significant longer PFS than those received non-pemetrexed chemotherapy (209 vs. 146 days, P ¼ 0.0107). In pemetrexed-treated cohorts, ROS1-positive patients with low TS expression had statistically significant longer PFS than those with high TS expression (184 vs. 110 days, P ¼ 0.0105). Conclusion: Crizotinib was also highly active at treating Chinese NSCLC patients with ROS1 rearrangement. TS expression could predict the efficacy of pemetrexedbased therapy in ROS1 fusion-positive patients. Background: Lung cancer is usually diagnosed at an advanced stage and survival has not improved in spite of several therapeutic advancements. Since most patients depend on palliative care, it is imperative to evaluate and maintain a satisfactory quality of life in them. This prospective study aimed to assess the quality of life related to health (QLRH) of patients attending a tertiary care hospital with lung cancer after chemotherapy treatment.
Methods:
The QLRH was assessed using the questionnaires Quality-of-Life Questionnaire-Core 30 (QLQ-C30) and Lung Cancer Module (LC13), version 3.0 among the patients attending a Tertiary care hospital in mangalore.
Results:
The sample was made up of 11 women and 19 men, with an average age of 68 years (51-87 years). After the chemotherapy treatment, the authors observed a clinically-relevant improvement in general quality of life, as well as in the symptoms of dyspnoea, insomnia, haemoptysis, cough, thoracic pain, pain in the arm/ shoulder, and financial difficulty. There was a worsening on the functional scale which assesses role performance and symptoms of fatigue, nausea and vomiting, sensory neuropathy, pain in other parts, constipation, loss of appetite and alopecia.
Conclusion: Although the patients have an improvement of their QLRH and symptoms related to the lung cancer after the chemotherapy treatment, there was a worsening of the symptoms which resulted from the toxicity of the chemotherapy medications. Results: Among all patients, the percentages of lung squamous cell carcinoma subtypes were: 68.5% (252/ 368), 26.2% (97/368), and 5.1% (19/368) for keratinizing squamous cell carcinoma (KSCC), nonkeratinizing squamous cell carcinoma (NKSCC), and basaloid squamous cell carcinoma (BSCC), respectively. There were more smokers in patients with KSCC than in patients with other subtypes (p¼0.004). There were no significant relationships between pathological subtypes and other clinicopathologic features, such as gender, age, location type, type of resection, stage, visceral pleural involvement, lymphovascular invasion, and lymph node involvement. The expressions of P40, CK5/6, TTF-1, Napsin A, and CK7 were also not significantly different in three subtypes.
Conclusion:
Our study revealed that there were no significant relationships between clinicopathologic features and lung squamous cell carcinoma subtypes. Background: Superior vena cava (SVC) can be involved in many ways in patients with lung cancer. This latter is considered to be the most frequent cause of SVC syndrome which is a medical emergency requiring prompt evaluation and treatment. The SVC syndrome can reveal the disease or can be discovered on computed tomography (CT) of the chest. The objectives of our study are to specify CT characteristics of SVC involvement in T4classed lung cancer and to estimate the frequency of its total obstruction in this patients category. Methods: Retrospective review of CT scans of 177 consecutive patients with T4-classed lung cancer, newly and fully diagnosed in our institution during the year 2015. All CT examinations were performed after contrast agent administration. Only patients with mediastinal involvement were retained. Every aspect of SVC involvement was noticed separately.
Results: Among the 177 patients, mediastinal invasion was observed in 132 cases (74.5%). SVC was involved in 32 cases (24%). Lung cancer was located on the right side in 91% of cases. The involvement included: -A contact with the tumor with loss of the fat layer (n¼ 7) -An inclusion of the vessel in the tumoral mass with narrowing of the lumen (n¼17) -An intraluminal tumoral bud (n¼8) -A complete obliteration (n¼ 6) Collateral venous circulation was observed in 8 cases. Adenocarcinoma and small cell lung cancer were the most frequent histological types responsible for SVC involvement Clinical signs of SVC syndrome were obvious in only 6 patients.
Conclusion: Superior vena cava involvement is quite frequent in advanced stage of lung cancer. However, the total tumoral obstruction of this vessel is rare. CT helps defining the mechanism and the severity of the SVC involvement.
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